James Creeden

1.1k total citations
26 papers, 483 citations indexed

About

James Creeden is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, James Creeden has authored 26 papers receiving a total of 483 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in James Creeden's work include Cancer Immunotherapy and Biomarkers (9 papers), Cancer Genomics and Diagnostics (8 papers) and Lung Cancer Treatments and Mutations (8 papers). James Creeden is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Cancer Genomics and Diagnostics (8 papers) and Lung Cancer Treatments and Mutations (8 papers). James Creeden collaborates with scholars based in United States, Switzerland and United Kingdom. James Creeden's co-authors include Peter C. Taylor, Richard S.P. Huang, Jeffrey S. Ross, Ole Gjoerup, Alexa B. Schrock, Geoffrey R. Oxnard, Nandini Hadker, Marlene Gyldmark, Talia Foster and Khaled Tolba and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

James Creeden

25 papers receiving 467 citations

Peers

Countries citing papers authored by James Creeden

Since Specialization

Citations

This map shows the geographic impact of James Creeden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Creeden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Creeden more than expected).

Fields of papers citing papers by James Creeden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Creeden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Creeden. The network helps show where James Creeden may publish in the future.

Co-authorship network of co-authors of James Creeden

This figure shows the co-authorship network connecting the top 25 collaborators of James Creeden. A scholar is included among the top collaborators of James Creeden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Creeden. James Creeden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Stakeholders' expectations of precision medicine: A qualitative study to identify areas of (mis)alignment 2023 ·Health Science Reports ·(unknown), James Creeden, (unknown), (unknown), Lidewij Eva Vat, (unknown), (unknown)	2
2	Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles 2023 ·The Oncologist ·(unknown), Jonathan W. Riess, Margaret E. McLaughlin-Drubin, Richard S.P. Huang, (unknown), James Creeden, Brian M. Alexander, Rachel Erlich	4
3	Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma 2022 ·JCO Precision Oncology ·Ryon P. Graf, Virginia Fisher, Richard S.P. Huang, (unknown), Ole Gjoerup, Jennifer J. Stanke, James Creeden, Mia Levy, Geoffrey R. Oxnard, Shilpa Gupta	14
4	Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer 2022 ·Cancer Research Communications ·Ryon P. Graf, Virginia Fisher, James Creeden, Alexa B. Schrock, Jeffrey S. Ross, Halla Nimeiri, Geoffrey R. Oxnard, Samuel J. Klempner	7
5	Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases 2022 ·The Oncologist ·Richard S.P. Huang, (unknown), Brennan Decker, Matthew Hiemenz, Karthikeyan Murugesan, James Creeden, Khaled Tolba, Laura P. Stabile, Shakti Ramkissoon, Timothy F. Burns, Jeffrey S. Ross	28
6	Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer 2022 ·JAMA Network Open ·Ryon P. Graf, Virginia Fisher, Janick Weberpals, Ole Gjoerup, (unknown), Richard S.P. Huang, Nicolas Sayegh, Douglas I. Lin, (unknown), Alexa B. Schrock, Eric A. Severson, James Haberberger, Jeffrey S. Ross, James Creeden, Mia Levy, Brian M. Alexander, Geoffrey R. Oxnard, Neeraj Agarwal	45
7	Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression 2021 ·Journal for ImmunoTherapy of Cancer ·Richard S.P. Huang, Brennan Decker, Karthikeyan Murugesan, Matthew Hiemenz, Douglas A. Mata, Gerald Li, James Creeden, Shakti Ramkissoon, Jeffrey S. Ross	8
8	The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA 2021 ·Clinical Cancer Research ·Jessica Lee, Mehlika Hazar-Rethinam, Brennan Decker, Ole Gjoerup, Russell W. Madison, Daniel S. Lieber, Jon Chung, Alexa B. Schrock, James Creeden, Jeffrey M. Venstrom, Brian M. Alexander, Geoffrey R. Oxnard	28
9	Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer 2021 ·European Urology ·Ryon P. Graf, Virginia Fisher, Joaquı́n Mateo, Ole Gjoerup, Russell W. Madison, (unknown), Hanna Tukachinsky, James Creeden, (unknown), Richard S.P. Huang, Douglas A. Mata, Jeffrey S. Ross, Geoffrey R. Oxnard, Jeffrey M. Venstrom, Amado J. Zurita	25
10	Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas 2021 ·The Oncologist ·Richard S.P. Huang, James Haberberger, (unknown), Eric A. Severson, Daniel Duncan, (unknown), Amanda Hemmerich, Claire Edgerly, Karthikeyan Murugesan, (unknown), (unknown), Oliver Holmes, Matthew Hiemenz, Jeffrey M. Venstrom, Julia A. Elvin, James Creeden, Douglas I. Lin, Jeffrey S. Ross, Shakti Ramkissoon	9
11	STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib 2021 ·JCO Precision Oncology ·Andrew D. Kelly, Tom Wiklund, Juha Kononen, James Creeden	3
12	Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors 2020 ·The AAPS Journal ·Ole Gjoerup, Charlotte A. Brown, Jeffrey S. Ross, Richard S.P. Huang, Alexa B. Schrock, James Creeden, David Fabrizio, Khaled Tolba	36
13	Are there financial savings associated with supplementing current diagnostic practice for preeclampsia with a novel test? Learnings from a modeling analysis from a German payer perspective 2013 ·Hypertension in Pregnancy ·Nandini Hadker, (unknown), (unknown), (unknown), James Creeden	12
14	Building Bridges to the Future of Medicine: Recommendations for Boosting Development of Novel and Companion Diagnostics 2012 ·Pharmacogenomics ·James Creeden	3
15	Serum Tests for Colorectal Cancer Screening 2011 ·Molecular Diagnosis & Therapy ·James Creeden, (unknown), (unknown), Douglas K. Rex	22
16	A Systematic Review of Serum Biomarkers Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor as Tests for Rheumatoid Arthritis 2011 ·SHILAP Revista de lepidopterología ·Peter C. Taylor, (unknown), (unknown), James Creeden	122
17	Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspective 2010 ·Journal of Medical Economics ·Nandini Hadker, (unknown), (unknown), Jeffrey D. Miller, Talia Foster, (unknown), James Creeden	47
18	Cost-Effectiveness of Erlotinib versus Docetaxel for Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in the United Kingdom 2010 ·Journal of International Medical Research ·(unknown), Michael Peake, (unknown), Marlene Gyldmark, (unknown), James Creeden, (unknown)	36
19	PCV49 FINANCIAL IMPACT OF A NOVEL PREECLAMPSIA DIAGNOSTIC TEST VS. STANDARD CARE: A DECISION-ANALYTIC MODELING ANALYSIS FROM A GERMAN HEALTH CARE PAYER PERSPECTIVE 2009 ·Value in Health ·Nandini Hadker, (unknown), (unknown), (unknown), (unknown), (unknown), James Creeden	2
20	The Cost-Effectiveness of Rituximab, Cyclophosphamide, Vincristine and Prednisolone (RCVP) Compared with CVP for the Treatment of Follicular Non-Hodgkin’s Lymphoma (NHL) in the UK. 2006 ·Blood ·Gavin Lewis, Robert Marcus, Stephen J. Proctor, Marlene Gyldmark, James Creeden, (unknown), F Jost	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact